Briscoe’s shrinking margins didn’t spook investors.
Dual-listed company’s shares fell more than 20% a day before the draft decision was announced to ASX.
After initially forecasting a $5m tariff hit for FY26, the company now expects it will be closer to $2.5m.
Helen Lofthouse is stepping down as chief executive, with no replacement announced as the ASX goes on a global search.
Heine has sailed the company through choppy waters after Steven Newman’s 2022 resignation.
CBA surge buoys Australia’s market.
Regulatory and policy issues in China and the US, which delivers 50% of revenues, have hit Australia’s largest listed biotech company's sales of vaccine and blood plasma products.
Vulcan led the benchmark higher on its latest broker upgrade.
Worse than expected trading has chewed into the carpet-maker’s cash reserves, lower the potential capital return to investors if a deal to sell the business goes through.
Skellerup marched higher on an upgrade by Craigs Investment Partners.